科技生物：英国引领创新前沿

TechBioUK leads innovation frontier Forewords The big picture for TechBio6 The annual state of TechBio8 UK companies driving innovation10 TechBio innovation showcase14Tailor Bio14ExpressionEdits15Aparito17Enhanc3D Genomics19OutSee22 Access to data – the UK SME picture24 BIA and TechBio28 BIA impact: Championing TechBio innovation in the UK28Closing the skills gap: #BIGIMPACT campaign update29TechBio Boost: A catalyst for growth30 Join theBIA TechBio network31 About BIA 32 I’m often asked what TechBio is, and I struggleto offer an easy definition. As this reportdemonstrates, it is not limited to one technologyor business model. In 2024 I see TechBio asa state of mind – an approach emerging incompanies large and small at the interface ofdata, AI, life science and innovation. And what’sclear is that the UK has unique assets andcapabilities to grow world-leading companiesin this extremely rich opportunity space. Steve Bates OBECEO, BIA This report highlights some of the key companies, deals and approaches we areseeing across the community that we are proud to represent. It’s great that global players, like Eli Lilly, are attracted to and are investing in UKlife science. Their acquisition of Aparito this year is in itself an interesting story ofa UK TechBio scale-up. Established in 2014 as part of the Bethnal Green VenturesAccelerator, the now Wrexham-based business set up by female founder Dr Elin HafDavies was part-funded by the Development Bank of Wales and received an initialreturn of 2.9 times on their £1.2 million equity investment on exit this year. I may bebiased but I think providing quality jobs in north Wales through accelerating globaldrug development by digitising decentralised clinical trials is more important thangetting a football club into League One with Hollywood backers. This year, we’ve witnessed remarkable progress in TechBio, highlighted bythe emergence of innovative companies like Isomorphic Labs and OutSee,demonstrating the UK's strength in AI-driven drug discovery and genomics analysis.Landmark partnerships, such as AstraZeneca’s collaboration with Immunai toenhance cancer drug trials, further showcase the sector's potential. I’m glad to see that being organised as a community is starting to produce benefitsto companies, not just with visibility and investment but also as a strong voice inthe UK ecosystem. A significant development this year has been the decision by the Secretary of Statefor Health, Wes Streeting, to direct NHSE to share GP data with UK’s nationallyconsented cohorts. This long-awaited change will allow UK Biobank and otherresearch cohorts to access deidentified participant data, supercharging thepotential of these valuable data assets. This is excellent news for innovators across the life science sector, and as our survey of members shows it is precisely theseNHS data sets on which UK SMEs see the greatest value in working in the yearsahead. We look forward to collaborating with UK Biobank to ensure that the datacan be used by UK scaling companies, for the most innovative purposes, followingtheir recent data access policy change so the country can reap the full economicbenefit in terms of company growth as a result of taxpayers investment in it. Our #BIGIMPACT campaign has attracted and engaged a talent pool of over 300students interested in roles in this emerging sector – I encourage companies toengage with it to secure the talent you need to grow to scale. As the TechBio sector continues to mature, we remain committed to fosteringcollaboration, supporting innovation, and addressing key challenges to ensuresustainable growth. Together, we can shape the future of healthcare and improvethe lives of millions of people worldwide. TechBiolies at the interface between atechnology-first mindset and a biology-drivenapproach to transform healthcare and acceleratedrug discovery. By harnessing the power ofAI-driven technologies and multidisciplinarytechnology and science teams such as engineers,computer scientists, and biologists, TechBiocompanies can unveil diagnostic solutions anddiscover innovative treatments at a pace neverseen before. Bianca De BlasiPhD in ComputationalBiology, Senior DataScientist, Citeline Over the past year, there has been a rise in partnership activity aimed at combiningand leveraging AI-driven technologies and biochemical expertise to acceleratethe drug development pipeline and time to market, across companies. Forinstance, the deal signed between Novo Nordisk and Valo Health will power thenext-generation drug discovery and development processes for cardiometabolicdiseases and beyond, through a team of interdisciplinary drug discovery scientistsand engineers. New partnerships also allow the use of multidimensional datasetsand platforms, as in the collaboration between Moderna and Immatics, whichcombines Moderna’s mRNA technologies and Immatics’ physiological and tumortissue datasets to discover novel therapies. In the past year,